-
PVCT Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
-
Shorts
Provectus Biopharmaceuticals (PVCT)
Company Profile
Quarter (USD) | Dec 24 | Sep 24 | Jun 24 | Mar 24 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 797.17 k | 797.17 k | 797.17 k | 797.17 k | 797.17 k | 797.17 k |
Cash burn (monthly) | 1.49 k | 19.14 k | 778.18 k | 377.70 k | 304.00 k | 273.67 k |
Cash used (since last report) | 5.40 k | 69.20 k | 2.81 mm | 1.37 mm | 1.10 mm | 989.73 k |
Cash remaining | 791.77 k | 727.96 k | -2.02 mm | -568.76 k | -302.24 k | -192.56 k |
Runway (months of cash) | 530.4 | 38.0 | -2.6 | -1.5 | -1.0 | -0.7 |
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 15.63 mm |
Total shares | 130.19 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Home Federal Bank Of Tennessee | 100.00 k | $12.00 mm |
LBMC Investment Advisors | 20.00 k | $2.40 mm |
Financial Symmetry | 10.19 k | $1.22 mm |
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 25 | Pershing Edward | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 7,551 | 0.00 | 2,063,538 |
11 Apr 25 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Option exercise | Dispose M | No | No | 2.862 | - | 20.00 k | - |
4 Apr 25 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Grant | Acquire A | No | No | 2.862 | - | 90.00 k | - |
26 Mar 25 | Pershing Edward | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 150,975 | 0.00 | 2,055,987 |
26 Mar 25 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Option exercise | Dispose M | No | No | 2.862 | - | 400.00 k | - |
21 Mar 25 | Pershing Edward | Series D-1 Convertible Preferred Stock Common Stock | Option exercise | Acquire M | No | No | 0 | 9,436 | 0.00 | 1,905,012 |
21 Mar 25 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Option exercise | Dispose M | No | No | 2.862 | - | 25.00 k | - |
20 Mar 25 | Pershing Edward | 8% Unsecured Convertible Promissory Note [object Object] | Grant | Acquire A | No | No | 2.862 | - | 130.00 k | - |